Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Limited reported strong full-year results for FY26 with revenue from operations at Rs 1,407 crore (vs Rs 934 crore in 9-month FY25). Net profit grew 39.5% to Rs 327 crore from Rs 234 crore. EPS improved to Rs 196.94 from Rs 141.22. The Board recommended a final dividend of Rs 45 per share, which together with Rs 160 interim dividend already paid totals Rs 205 per share for the year. Note: FY25 was only 9 months due to change in financial year-end from June to March, making direct comparisons challenging. Operating cash flow remained robust at Rs 338 crore. Statutory auditors Haribhakti & Co. LLP issued an unmodified opinion with no qualifications.
The company delivered robust double-digit revenue and profit growth, indicating strong operational performance in its pharmaceuticals business. Shareholders can expect positive sentiment given healthy profit growth, cash generation, and substantial dividend payout. The clean audit report with unmodified opinion removes any concerns.